Schering Intron A/Rebetol Treatment-Naive Hepatitis C Data Close To Filing

Data from naive chronic hepatitis C patients treated with Schering-Plough's Intron A/Rebetol combination therapy are being analyzed, Schering Hepatology Clinical Director Janice Albrecht, MD, told FDA's Antiviral Drugs Advisory Committee May 4.